Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | $-133M | $-194M | $-126M | -188.7% | 104.5% | -14.6% |
| 2024 | $83M | $-198M | $-227M | $-176M | -87.5% | -7.7% | -13.8% |
| 2023 | $90M | $-239M | $-263M | $-228M | -84.5% | -19.9% | -6.0% |
| 2022 | $113M | $-244M | $-280M | $-238M | -54.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 170.44 |
| Operating Revenue | 170.44 |
| Cost Of Revenue | 20.30 |
| Gross Profit | 150.14 |
| Operating Expense | 311.34 |
| Research And Development | 228.30 |
| Selling General And Administration | 82.86 |
| Total Expenses | 331.64 |
| Operating Income | -161.20 |
| Total Operating Income As Reported | -161.20 |
| EBITDA | -133.26 |
| Normalized EBITDA | -145.50 |
| EBIT | -148.87 |
| Interest Income | 0.08 |
| Interest Expense | 45.01 |
| Net Interest Income | -44.92 |
| Other Income Expense | 12.24 |
| Interest Income Non Operating | 0.08 |
| Interest Expense Non Operating | 45.01 |
| Net Non Operating Interest Income Expense | -44.92 |
| Pretax Income | -193.88 |
| Tax Provision | - |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -193.88 |
| Net Income From Continuing And Discontinued Operation | -193.88 |
| Net Income From Continuing Operation Net Minority Interest | -193.88 |
| Net Income | -193.88 |
| Net Income Common Stockholders | -193.88 |
| Net Income Including Noncontrolling Interests | -193.88 |
| Normalized Income | -206.12 |
| Diluted NI Availto Com Stockholders | -193.88 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 15.62 |
| Reconciled Cost Of Revenue | 20.30 |
| Total Unusual Items | 12.24 |
| Total Unusual Items Excluding Goodwill | 12.24 |
| Special Income Charges | 0 |
| Impairment Of Capital Assets | 0 |
| Gain On Sale Of Security | 12.24 |
| General And Administrative Expense | 82.86 |
| Other Gand A | 82.86 |
| Other Operating Expenses | 0.18 |
| Provision For Doubtful Accounts | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| REGENXBIO Inc.this co. | RGNX | $356M | -1.83 | 3.46 | -188.7% | -2.96 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Puma Biotechnology, Inc. | PBYI | $357M | 11.47 | 2.74 | 23.9% | 6.67 |
| Atea Pharmaceuticals, Inc. | AVIR | $354M |
| - |
| - |
| - |
| - |
| - |
| -2.23 |
| 1.28 |
| -57.5% |
| -1.43 |
| Greenwich LifeSciences, Inc. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Larimar Therapeutics, Inc. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M | -1.62 | 5.93 | -366.2% | -1.07 |
| Peer Median | - | -2.23 | 3.86 | -92.0% | -1.25 | |